X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

System-State: Number of processed items 46.923 Notifications successully processed since Inception
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US54303L1044
State: 19.01.2025 | 9AM
Do you already know our new terminal view? Click here.
FIGI: -
LGVN

Longeveron Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Longeveron Inc.
ISIN
US54303L1044
TICKER
LGVN
MIC
XNAS
REUTERS
LGVN.OQ
BLOOMBERG
LGVN US
Wed, 18.12.2024       Longeveron

Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Mon, 02.12.2024       Longeveron

Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Mon, 11.11.2024       Longeveron

Longeveron has appointed Devin Blass as Chief Technology Officer (CTO) and SVP of CMC, effective Dec 2, adding capabilities ahead of potential BLA filing.
Tue, 29.10.2024       Longeveron

Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Sun, 27.10.2024       Longeveron

Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
Mon, 14.10.2024       Longeveron

Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Wed, 09.10.2024       Longeveron

Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
Mon, 07.10.2024       Longeveron

Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Wed, 02.10.2024       Longeveron

Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Thu, 26.09.2024       Longeveron

Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Mon, 26.08.2024       Longeveron

Longeveron to present at HC Wainwright global investment conference.
Sun, 28.07.2024       Longeveron

Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Fri, 19.07.2024       Longeveron

Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds.
Tue, 09.07.2024       Longeveron

Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
Mon, 08.07.2024       Longeveron

Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Tue, 18.06.2024       Longeveron

Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B
Mon, 17.06.2024       Longeveron

Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Tue, 28.05.2024       Longeveron

Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
Fri, 10.05.2024       Longeveron

Longeveron announces planned transitions on its Board of Directors.
Thu, 02.05.2024       Longeveron

Longeveron to report Q1 2024 financial results on May 14, 2024.

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.